MedElevator
Войти в исследования IJID regions · 2026
Prevalence and epidemiology of hepatitis B and hepatitis D in Uzbekistan-results from a population-based serosurvey, 2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Musabaev Erkin, Tohme Rania A, Joldasova Elizaveta, Karamatova Shakhida, Khodiev Aybek, Kan Nataliya, Abdurasulov Abdulaziz, Khodjaeva Malika, Kurbanov Botirjon, Abdurakhimova Zulfiya, Mirdjalilov Dilafkor, Kamili Saleem, Shadaker Shaun, Khetsuriani Nino
Аннотация
OBJECTIVES: Uzbekistan, historically a country with high hepatitis B virus (HBV) infection endemicity, introduced infant hepatitis B vaccination in 2001 and has sustained ≥90% coverage for hepatitis B vaccine birth dose (HepB-BD) and three or more doses. In 2017, Uzbekistan initiated hepatitis B elimination activities. However, data on hepatitis B prevalence in the general population were lacking.
METHODS: In 2022, we conducted a serosurvey among persons aged ≥5 years using stratified cluster sampling. Blood samples were tested for markers of HBV and hepatitis D virus (HDV) infections.
RESULTS: We enrolled 9063 adults aged ≥18 years and 4092 children aged 5-17 years. Overall weighted prevalence of HBV surface antigen (HBsAg) was 4.1% (95% confidence interval, 3.1-5.0%); 13.0% (7.8-20.8%) of HBsAg-positive persons had detectable HDV ribonucleic acid (RNA). HBsAg prevalence was lowest (0.4%) among 5-14-year-olds and highest (7.3%) among 40-49-year-olds. Children who had not received HepB-BD had higher HBsAg prevalence (2.3%) than those who had received HepB-BD (0.1%, P < 0.001).
CONCLUSION: Successful hepatitis B vaccination resulted in low HBV infection prevalence among children, but hepatitis B remains widespread among adults in Uzbekistan. Expanding HBV prevention, screening, and treatment among adults, and maintaining high infant vaccination coverage may help achieve hepatitis B elimination in Uzbekistan.
METHODS: In 2022, we conducted a serosurvey among persons aged ≥5 years using stratified cluster sampling. Blood samples were tested for markers of HBV and hepatitis D virus (HDV) infections.
RESULTS: We enrolled 9063 adults aged ≥18 years and 4092 children aged 5-17 years. Overall weighted prevalence of HBV surface antigen (HBsAg) was 4.1% (95% confidence interval, 3.1-5.0%); 13.0% (7.8-20.8%) of HBsAg-positive persons had detectable HDV ribonucleic acid (RNA). HBsAg prevalence was lowest (0.4%) among 5-14-year-olds and highest (7.3%) among 40-49-year-olds. Children who had not received HepB-BD had higher HBsAg prevalence (2.3%) than those who had received HepB-BD (0.1%, P < 0.001).
CONCLUSION: Successful hepatitis B vaccination resulted in low HBV infection prevalence among children, but hepatitis B remains widespread among adults in Uzbekistan. Expanding HBV prevention, screening, and treatment among adults, and maintaining high infant vaccination coverage may help achieve hepatitis B elimination in Uzbekistan.